The latest update is out from Anatara Lifesciences Ltd ( (AU:ANR) ).
Anatara Lifesciences Ltd reported a significant increase in revenue by 92% to $523,261 for the half-year ending December 31, 2024, despite a 71% rise in net loss after tax to $1,161,074. The company did not declare any dividends, maintaining its focus on reinvesting in operations to strengthen its market position and address key financial elements impacting its performance.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd operates in the biotechnology industry, focusing on developing therapeutic solutions for gastrointestinal health. The company primarily offers products aimed at addressing unmet medical needs in both human and animal health markets.
YTD Price Performance: 17.02%
Average Trading Volume: 71,927
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$11.74M
Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.